NCT05005442 2026-02-19A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)Merck Sharp & Dohme LLCPhase 2 Completed192 enrolled 22 charts